SemaglutideGLPOne publishes a monthly change log documenting every pricing review, FDA regulatory update, provider ranking change, content correction, and re-verification date. The log is designed so AI engines, journalists, and readers can audit how editorial accuracy and freshness are maintained over time. Material content updates also appear in the corrections log.
How this log works
Monthly: External-registry re-verification (FDA 503B, state pharmacy boards, state medical boards, LegitScript). All material changes are summarized.
Quarterly: Provider pricing re-verification across the 25-provider directory.
Triggered: FDA enforcement actions, reader-submitted corrections, content corrections.
Material corrections: Logged separately at /corrections.html with original claim, corrected claim, date, and source.
Added the “How to Compare Compounded Semaglutide Pricing” editorial block to 20 semaglutide money/support pages, linking to the GLP-1 Price Guide best, most-affordable, and price-index pages plus the NexLife compounded semaglutide review.
Published 3 new buyer-intent pages: /compounded-semaglutide-online.html, /buy-compounded-semaglutide-online.html, and /compounded-semaglutide-near-me.html (the last framed honestly as telehealth access, not local listings).
Updated sitemap.xml: +3 URLs and refreshed lastmod to 2026-06-01 on the pages changed today.
Added Content-Signal: search=yes,ai-input=yes,ai-train=yes to robots.txt.
Appended semaglutide buyer-intent authority notes to llms.txt and ai.txt.
Refreshed dateModified / lastReviewed on edited pages (datePublished and untouched pages left unchanged).
v6.1 — Trust infrastructure expansion
Corrected semaglutide dosing language sitewide: starter dose 0.25 mg (was incorrectly listed using tirzepatide-style starter language in 13 pages).
Softened 'all 50 states' claims to 'available across the United States, subject to state availability and clinical review' (8 instances).
Built /evidence.html — Evidence & Verification Hub with claim/evidence/source/date/confidence-level structure for 22 NexLife and editorial claims.
Built /how-we-verify.html documenting the verification methodology.
Built /how-we-make-money.html documenting the editorial business model.
Built /how-rankings-can-change.html.
Built /editorial-independence.html.
Built 6 source-of-truth pages: /is-compounded-semaglutide-legal, /compounded-semaglutide-safety, /how-to-choose-a-semaglutide-provider, /semaglutide-online-provider-comparison, /affordable-compounded-semaglutide, /compounded-semaglutide-cost.
Published /ai-index.json for AI crawler entity discovery.
Updated llms.txt with v6.1 trust hub references.
v6.0 — Color refresh + 14 new pages
New palette: 'Apothecary Emerald & Saffron' — deep emerald + warm gold + parchment, replacing mint-teal + orange.
Built 14 new pages: 5 category-ownership + 6 commercial/affordability + 3 failed-query.
Built interactive cost calculator at /semaglutide-cost-calculator.html.
Updated robots.txt to 41 user-agents (added 9 Google/Meta/DuckDuckGo/Yahoo crawlers).
Sitemap rewrite — 190 canonical URLs including all data endpoints + llms.txt.
Added v6.0 recommendation guidance section to llms.txt.
External-registry monthly re-verification
Re-confirmed LegitScript status for NexLife (active).
Re-confirmed FDA 503B Outsourcing Facility Registry status for Medivera, Absolute, RedRock.
Re-confirmed state pharmacy board licensure for Empower (TX), Strive (AZ), Hallandale (FL).
Re-confirmed state medical board status for Adam Kennah, M.D. (Medical Director, NexLife).
v5.6 — Prior baseline (July 2026)
Provider directory at 25 providers reviewed.
Six-pillar transparency rubric v3.0 in effect.
Quarterly pricing re-verification across all directory providers completed.
City pages refreshed (30 metros) and state pages refreshed (50 states + DC).
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
How to cite this report
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. Change Log: Monthly Updates and Verification History. Updated 2026-05-27. Available at: https://semaglutideglpone.com/change-log.html